Publications by authors named "Zitong B Jia"
Article Synopsis
- A model was developed to estimate the reduction in opioid abuse-related events and cost savings in the US by replacing current extended-release opioids with extended-release abuse-deterrent opioids.
- The potential reductions in abuse-related medical events are projected to be between 13-31%, translating to approximately 78,000-186,000 fewer emergency department visits and annual savings of $640 million to $1.538 billion.
- The findings suggest that replacing extended-release oxycodone yields the greatest cost savings and reduction in events, whereas transdermal fentanyl replacement offers the least, with agonist/antagonist technologies providing higher savings than physical/chemical barrier technologies.
Opioid Abuse: A Detailed Examination of Cost Drivers over a 24-Month Follow-up Period.
J Manag Care Spec Pharm
November 2017
Background: Previous work has documented the considerable economic burden associated with opioid abuse, dependence, and overdose/poisoning (hereafter, "abuse"). Recent analyses have provided insights into the trajectory and drivers of the excess costs of abuse both before and after diagnosis, showing the important role of other substance abuse, mental health issues, and painful conditions.
Objective: To build on the recently published study by Kirson et al.
Objectives: To replicate and extend a recently published analysis of the drivers of excess costs of opioid abuse.
Study Design: Retrospective data analysis using de-identified claims data from the Truven MarketScan Commercial Claims and Encounter database.
Methods: Medical and prescription drug claims from beneficiaries covered by large self-insured US companies were used to select patients with incident diagnoses of opioid abuse between 2012 and 2015.